Other Events ·
Immuron reports Q1 FY27 global sales of AUD$2.2 million, up 9% year-over-year
IMRNImmuron Ltd
Immuron Limited reported unaudited first-quarter fiscal 2027 global sales of AUD$2.2 million, representing a 9% increase compared to the prior comparative period and a 5% rise from the previous quarter. Australian sales contributed AUD$1.8 million, up 14% year-over-year, driven by a successful brand re-launch of Travelan® that outpaced category growth. Canadian sales surged 286% to AUD$0.1 million following increased awareness and sampling at major conferences. Conversely, U.S. sales declined 19% to AUD$0.3 million due to high prior-year purchases during Amazon Prime Day and temporary logistics delays, though inventory has since been replenished. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.